Gastroenterology Phase 1 Deal Benchmarks (2026)

Understanding Gastroenterology Deal Benchmarks at Phase 1

Phase 1 Gastroenterology licensing deals command a median upfront payment of $134M, with values ranging from $57M at the low end to $216M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the gastroenterology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $589M to $1.7B, with a median of $1.1B. Royalty rates for gastroenterology assets at this stage typically fall between 5.4% and 10.7% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.